Open AccessProgress of modern imaging modalities in multiple myeloma
Author(s) -
Toshiki Terao,
Kosei Matsue
Publication year - 2022
Publication title -
international journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.836
H-Index - 75
eISSN - 1865-3774
pISSN - 0925-5710
DOI - 10.1007/s12185-022-03360-6
Subject(s) - medicine , multiple myeloma , positron emission tomography , magnetic resonance imaging , radiology , malignancy , hematologic malignancy , computed tomography , nuclear medicine , modalities , hematology , medical imaging , medical physics , pathology , social science , sociology
Multiple myeloma (MM) is an incurable hematological malignancy, but treatment advances made in the last two decades have markedly improved its prognosis. Imaging has played a particularly important role in the management of myeloma. Whole-body low-dose computed tomography (WBLDCT) is replacing conventional skeletal survey by whole-body X-rays. In addition, magnetic resonance imaging (MRI) and positron-emission tomography/computed tomography (PET/CT) have become important imaging modalities not only for MM diagnosis but also for assessment of myeloma cell infiltration, extramedullary disease, treatment efficacy, and prognosis. However, there is room to improve their accuracy and specificity for assessment of treatment response, tumor volume, and residual disease. This review introduces novel diagnostic techniques, such as WBLDCT, MRI, and PET/CT, discusses their contribution to MM care, and lists areas for future research.